Delivery Order SPE2DR25D1100-SPE2DR26FCU7C
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Provocholine inhalation solution in 18ml pack quantities, with a ceiling value of $2,210. The contract, awarded on September 8, 2025, represents a firm fixed-price delivery order with a completion deadline of September 9, 2025. This award utilizes no set-aside designation and is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $5,501.30 to AmerisourceBergen Drug Corp for Provocholine inhalation solution in 18ML packs, with performance in Conshohocken, Pennsylvania and completion by September 4, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at approximately $1 billion through...
- The Defense Logistics Agency awarded a $5,501.30 delivery order to AmerisourceBergen Drug Corp for Provocholine inhalation solution in 18ML packs, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The order is a child delivery order issued under AmerisourceBergen's larger indefinite delivery contract with...
- The Defense Logistics Agency awarded a $2,039.43 delivery order to AmerisourceBergen Drug Corp for Provocholine inhalation solution in 18ML packs, with performance in Conshohocken, Pennsylvania and completion scheduled for November 5, 2025. This is a firm fixed-price delivery order issued without set-aside designation, reflecting competitive award to the prime contractor based on open competition capabilities. The delivery order represents a child action under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Provocholine inhalation solution in an 18ML pack configuration, valued at $10,776.17 under a firm fixed-price contract type. The award, issued on December 15, 2025, with an ultimate completion date of December 16, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. This delivery order is a child contract executed under...
- The Defense Logistics Agency awarded a delivery order valued at $16,503.90 to AmerisourceBergen Drug Corp for Provocholine inhalation solution in 18ML packs. This delivery order, issued on July 19, 2025, with an ultimate completion date of July 21, 2025, operates under a firm fixed price structure with no set-aside designation. The award represents a competitive procurement action through the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Provocholine Inhalation Solution in an 18mL pack configuration, with a firm fixed price ceiling value of $7,052.01. The award was made on December 11, 2025, with an ultimate completion date of December 12, 2025, and represents a non-set-aside, competitively awarded contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,650.39 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Provocholine inhalation solution in 18 mL packs. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA and is scheduled for completion by August 28, 2025. The product will be delivered to the contractor's facility in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $7,538.38 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on September 17, 2025, for Provocholine inhalation solution in 18-milliliter packs. The contract is set to be completed by September 18, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for Provocholine inhalation solution in 18mL packs, with a ceiling value of $7,016.62 and a firm fixed price structure. The order is scheduled for completion by September 24, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued as a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCU7CDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,597.80 to AmerisourceBergen Drug Corp for Provocholine Inhalation Solution in an 18 mL pack. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 16, 2025. The delivery order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order leverages AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, a prime vendor agreement valued at approximately $1 billion and running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through open competition. The company's pharmaceutical supply portfolio supports military and veteran healthcare systems across multiple therapeutic domains. Provocholine (methacholine chloride) is a bronchial challenge agent commonly used in pulmonary function testing to assess airway hyperresponsiveness. This delivery order represents one of numerous competitive awards the company has received from DLA for specialized pharmaceutical products and medical supplies supporting defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 12/14/25 |